We’re coming down to the wire for the post-Thanksgiving consumer rush that is Black Frinday and Cyber Monday. We’ve checked all of the deals below for accuracy, value, and, you know, whether they’re ...

Karen Read’s civil lawsuit has been moved from state court to federal court following a request by the attorney representing key witnesses at her murder trials who she has accused of framing her in ...

“I think we will be leaning into what’s going on now. The current state of affairs is daunting; the world is upside down and how do we navigate through this world of half-truths? What is real?

Christine is a freelance writer for Collider with two decades of experience covering all types of TV shows and movies spanning every genre. With a particular affinity for dramas, true crime, sitcoms, ...

Exact Sciences, one of Madison’s largest biotech companies, has agreed to be acquired by Abbott Laboratories for $23 billion, the Illinois-based company announced Thursday.

Abbott’s roughly $21 billion acquisition of cancer screening firm Exact Sciences lays out the company’s future strategy. Analysts said the acquisition not only marks Abbott’s foray into cancer ...

Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics ...

Good morning, and thank you for standing by. Welcome to Abbott's conference call. [Operator Instructions]. This call is being recorded by Abbott. With the exception of any participants' questions ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt. The ...

Abbott Laboratories ABT-1.10%decrease; red down pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS 0.04%increase; green up pointing triangle in a deal valued at about ...

In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for the diagnostics company. Three cancer test launches, multiple study readouts and one $23 ...